From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome

Clinical Therapeutics

Volumn 36, Issue 3, 2014, Pages 436-455

  Bogan, Richard K ^a  

^a SleepMed Inc   (United States)

Author keywords

augmentation; dopamine agonists; restless legs syndrome; rotigotine; transdermal

Indexed keywords

PLACEBO; PROLACTIN; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

APPLICATION SITE DISCOLORATION; APPLICATION SITE REACTION; ARTICLE; BLOOD LEVEL; CARCINOGENICITY; CATARACT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PHARMACOLOGY; CONTUSION; DISEASE EXACERBATION; DIVERTICULITIS; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ELECTROCARDIOGRAM; ERYTHEMA; FALLING; FATIGUE; HALLUCINATION; HEART ARRHYTHMIA; HEMATOMA; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; IN VITRO STUDY; LEYDIG CELL TUMOR; LONG TERM CARE; LUNG FIBROSIS; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; META ANALYSIS; NAUSEA; NONHUMAN; NONREM SLEEP; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PERIODIC LIMB MOVEMENT DISORDER; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; POLYSOMNOGRAPHY; PUBLICATION; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SIDE EFFECT; SINUS BRADYCARDIA; SLEEP DISORDER; SLEEP QUALITY; SOMNOLENCE; SPERMATOZOON ABNORMALITY; SPINAL ROOT; SYSTEMATIC REVIEW; TINNITUS; TRAFFIC ACCIDENT; TRANSDERMAL PATCH; UTERUS TUMOR; VOMITING; DRUG DELIVERY SYSTEM; FOOD AND DRUG ADMINISTRATION; INTRADERMAL DRUG ADMINISTRATION; MEDLINE; SLEEP; UNITED STATES;

ADMINISTRATION, CUTANEOUS; DOPAMINE AGONISTS; DRUG DELIVERY SYSTEMS; HUMANS; PUBMED; RESTLESS LEGS SYNDROME; SLEEP; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84896371564     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.01.021     Document Type: Review

References (73)

1. R.P. Allen, D. Picchietti, and W.A. Hening et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institutes of Health Sleep Med 4 2003 101 119
2. R.P. Allen, P. Stillman, and A.J. Myers Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: prevalence and characteristics Sleep Med 11 2010 31 37
3. R.P. Allen, M. Bharmal, and M. Calloway Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States Mov Disord 26 2011 114 120
4. C.J. Earley, and M.H. Silber Restless legs syndrome: understanding its consequences and the need for better treatment Sleep Med 11 2010 807 815
5. R.P. Allen, A.S. Walters, and J. Montplaisir et al. Restless legs syndrome prevalence and impact: REST general population study Arch Intern Med 165 2005 1286 1292
6. K.E. Innes, T.K. Selfe, and P. Agarwal Restless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: a systematic review Sleep Med Rev 16 2012 303 339
7. J.W. Winkelman, E. Shahar, and I. Sharief et al. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study Neurology 70 2008 35 42
8. M. Michaud, J. Paquet, and G. Lavigne et al. Sleep laboratory diagnosis of restless legs syndrome Eur Neurol 48 2002 108 113
9. C.J. Earley, R.P. Allen, and W. Hening Restless legs syndrome and periodic leg movements in sleep Handb Clin Neurol 99 2011 913 948
10. A.S. Walters, and D.B. Rye Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke Sleep 32 2009 589 597
11. J.W. Winkelman, L. Finn, and T. Young Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort Sleep Med 7 2006 545 552
12. D. García-Borreguero, P. Stillman, and H. Beneš et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care BMC Neurol 11 2011 28
13. C. Trenkwalder, and W. Paulus Restless legs syndrome: pathophysiology, clinical presentation and management Nat Rev Neurol 6 2010 337 346
14. R.P. Allen, and C.J. Earley The role of iron in restless legs syndrome Mov Disord 22 Suppl 18 2007 S440 S448
15. L. Ferini-Strambi RLS-like symptoms: differential diagnosis by history and clinical assessment Sleep Med 8 Suppl 2 2007 S3 S6
16. J. Winkelman, D. Czamara, and B. Schormair et al. Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1 PLoS Genet 7 2011 e1002171
17. H. Stefansson, D.B. Rye, and A. Hicks et al. A genetic risk factor for periodic limb movements in sleep N Engl J Med 357 2007 639 647
18. R. Byrne, S. Sinha, and K.R. Chaudhuri Restless legs syndrome: diagnosis and review of management options Neuropsychiatr Dis Treat 2 2006 155 164
19. D. Garcia-Borreguero, R. Kohnen, and M.H. Silber et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group Sleep Med 14 2013 675 684
20. E.D. Driver-Dunckley, B.N. Noble, and J.G. Hentz et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome Clin Neuropharmacol 30 2007 249 255
21. J.R. Cornelius, M. Tippmann-Peikert, and N.L. Slocumb et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study Sleep 33 2010 81 87
22. D.O. Lee, R.B. Ziman, and A.T. Perkins et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome J Clin Sleep Med 7 2011 282 292
23. R.K. Bogan, M.A. Bornemann, and C.A. Kushida et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study Mayo Clin Proc 85 2010 512 521
24. D. Tzonova, O. Larrosa, and E. Calvo et al. Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease) Sleep Med 13 2012 151 155
25. R. Lal, A. Ellenbogen, and D. Chen et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome Clin Neuropharmacol 35 2012 165 173
26. D. García-Borreguero, R.P. Allen, and R. Kohnen et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute Sleep Med 8 2007 520 530
27. R.P. Allen, and C.J. Earley Augmentation of the restless legs syndrome with carbidopa/levodopa Sleep 19 1996 205 213
28. D. García-Borreguero, and A.M. Williams Dopaminergic augmentation of restless legs syndrome Sleep Med Rev 14 2010 339 346
29. C. Guilleminault, M. Cetel, and P. Philip Dopaminergic treatment of restless legs and rebound phenomenon Neurology 43 1993 445
30. J.W. Winkelman, and L. Johnston Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS) Sleep Med 5 2004 9 14
31. C. Trenkwalder, H. Benes, and L. Grote et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial Mov Disord 22 2007 696 703
32. W. Paulus, and C. Trenkwalder Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome Lancet Neurol 5 2006 878 886
33. D. García-Borreguero, R.P. Allen, and H. Benes et al. Augmentation as a treatment complication of restless legs syndrome: concept and management Mov Disord 22 Suppl 18 2007 S476 S484
34. R.F. Pfeiffer A promising new technology for Parkinson's disease Neurology 65 2005 S6 S10
35. European Medicines Agency. Neupro: EPAR product information 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000626/WC500026397.pdf. Accessed November 2012.
36. W.H. Oertel, H. Beneš, and D. García-Borreguero et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe Sleep Med 9 2008 228 239
37. O. Rascol, and S. Perez-Lloret Rotigotine transdermal delivery for the treatment of Parkinson×s disease Exp Opin Pharmacother 10 2009 677 691
38. D. Scheller, C. Ullmer, and R. Berkels et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease Naunyn Schmiedebergs Arch Pharmacol 379 2009 73 86
39. W. Timmerman, I.N. Rusk, and P. Tepper et al. The effects of the enantiomers of the dopamine agonist N-0437 on food consumption and yawning behaviour in rats Eur J Pharmacol 174 1989 107 114
40. J. Kehr, X.J. Hu, and M. Goiny et al. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation J Neural Transm 114 2007 1027 1031
41. J.D. Belluzzi, E.F. Domino, and J.M. May et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease Mov Disord 9 1994 147 154
42. S. Rose, D.K. Scheller, and A. Breidenbach et al. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates Behav Pharmacol 18 2007 155 160
43. J.M. Beaulieu, and R.R. Gainetdinov The physiology, signaling, and pharmacology of dopamine receptors Pharmacol Rev 63 2011 182 217
44. European Medicines Agency. Neupro: EPAR scientific discussion. 2006. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000626/WC500026394.pdf. Accessed November 2012.
45. P.J. Swart, and R.A. De Zeeuw Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats Pharmazie 47 1992 613 615
46. P.J. Swart, and R.A. de Zeeuw Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats J Pharm Sci 82 1993 200 203
47. P.J. Swart, W.E. Oelen, and A.P. Bruins et al. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry J Anal Toxicol 18 1994 71 77
48. W. Cawello, M. Braun, and H. Boekens Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery Drug Metab Dispos 37 2009 2055 2060
49. C.M. Baldwin, and G.M. Keating Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease CNS Drugs 21 2007 1039 1055
50. K. Hansen, M. Braun, and R. Horstmann Low drug-drug interaction potential of rotigotine J Clin Pharmacol 45 2005 A1091 Abstract
51. M. Braun, W. Cawello, and H. Boekens et al. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine Br J Clin Pharmacol 67 2009 209 215
52. M. Braun, W. Cawello, and J.O. Andreas et al. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa J Clin Pharmacol 49 2009 1047 1055
53. Wolff HM, Seiffert T, Boddenberg A, et al. Drug release characteristics of rotigotine transdermal system. Presented at: 33rd Annual Meeting and Exposition of the Controlled Release Society. Vienna, Austria; 2006.
54. J.P. Elshoff, M. Braun, and J.O. Andreas et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies Clin Ther 34 2012 966 978
55. M. Braun, W. Cawello, and K. Poole et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease Eur J Neurol 12 96 2005 P1245 Abstract
56. Whitesides J, Cawello W, Woltering F, et al. Removal and new patch application during long-term treatment of patients with advanced Parkinson's disease. Presented at: 63rd Annual Meeting of the American Academy of Neurology. Honolulu, Hawaii; 2011.
57. W. Cawello, M. Braun, and R. Horstmann et al. Pharmacokinetics, safety and tolerability of rotigotine after transdermal patch administration in Japanese and Caucasian healthy subjects Mov Disord 21 suppl 2006 S547-S548:P9802. Abstract
58. W. Cawello, M. Braun, and R. Horstmann Impact of moderate impairment of hepatic function on the steady-state pharmacokinetics of transdermal rotigotine Eur J Neurol 14 199 2007 P2149 Abstract
59. W. Cawello, S. Ahrweiler, and W. Sulowicz et al. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function Br J Clin Pharmacol 73 2012 46 54
60. K. Stiasny-Kolster, R. Kohnen, and E. Schollmayer et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study Mov Disord 19 2004 1432 1438
61. C. Trenkwalder, H. Benes, and W. Poewe et al. Efficacy of rotigotine for treatment of moderate to severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial Lancet Neurol 7 2008 595 604
62. W.A. Hening, R.P. Allen, and W.G. Ondo et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States Mov Disord 25 2010 1675 1683
63. H. Beneš, D. García-Borreguero, and W. Oertel et al. Safety and efficacy of long-term treatment with transdermal rotigotine in patients with idiopathic Restless Legs Syndrome: a 12-month open-label extension study Mov Disord 25 Suppl 2 2010 S515
64. R.P. Allen, J.W. Winkelman, and W.G. Ondo et al. Long-term treatment with transdermal rotigotine in subjects with idiopathic restless legs syndrome (RLS): results from a 12-month open-label extension trial Sleep 33 2010 A251
65. H. Beneš, D. García-Borreguero, and L. Ferini-Strambi et al. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine Sleep Med 13 2012 589 597
66. B. Hogl, W.H. Oertel, and K. Stiasny-Kolster et al. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch BMC Neurol 10 2010 86
67. W. Oertel, C. Trenkwalder, and H. Beneš et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate to severe idiopathic restless legs syndrome: a 5-year open-label extension study Lancet Neurol 10 2011 710 720
68. W.H. Oertel, H. Benes, and D. Garcia-Borreguero et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome Sleep Med 9 2008 865 873
69. Y. Inoue, K. Hirata, and K. Hayashida et al. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome Prog Neuropsychopharmacol Biol Psychiatry 40 2013 326 333
70. W.H. Oertel, H. Benes, and D. Garcia-Borreguero et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study Sleep Med 2010 848 856
71. A.S. Walters, C. LeBrocq, and A. Dhar et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome Sleep Med 4 2003 121 132
72. R. Kohnen, K. Stiasny-Kolster, and W. Oertel et al. Severity rating of restless legs syndrome: validation of the RLS-6 scales Sleep 2004 27
73. A. Walters, R. Bogan, and W. Ondo et al. Sleep improvement with rotigotine in patients with idiopathic restless legs syndrome: results from two 6-month placebo-controlled trials Sleep 2011 34